Fig. 4From: Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectivesIngrowth of the radioactivity of the daughter nuclides of Ac-225 in percentage of the total activity (%) (a) ingrowth of the daughters in moles, calculated for a 10 MBq source of Ac-225 over time including the ingrowth of the stable decay product Bi-209 (b)Back to article page